Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer.
Tamoxifen, an antiestrogen which competes for the estrogen receptor, modulates natural killer cell activity in vivo. Seventeen post-menopausal stage I breast cancer patients received tamoxifen for 1 month and a statistically significant increase in NK activity was demonstrated (P = 0.0005). There was a small incremental shift in the number of Leu-11b positive cells. These data demonstrate that tamoxifen functions as a biological response modifier.
D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects*; D008593:Menopause; D008875:Middle Aged; D009367:Neoplasm Staging; D010641:Phenotype; D013629:Tamoxifen / Q000627:therapeutic use*
D013629:Tamoxifen